NCT04529499View on ClinicalTrials.gov

Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

August 22, 2020

Primary Completion Date

January 22, 2021

Study Completion Date

January 27, 2021

Conditions
Covid19
Interventions
DRUG

AVIGAN

Patients will be randomized to the favipiravir + supportive care group in a 1:1 ratio

DRUG

Placebo Comparator

Patients will be randomized to the placebo + supportive care group in a 1:1 ratio

Trial Locations (2)

47781

Jaber Al-Ahmad Al-Sabah Hospital (South Surra), Kuwait City

90005

Mishref Field Hospital (Mishref), Kuwait City

Sponsors
All Listed Sponsors
lead

Dr. Reddy's Laboratories Limited

INDUSTRY